Apr 22, 2021

| Rising Adoption of Advanced Techniques for Treating Acute Neurological Disorders are Factors Fueling Industry Growth, says Emergen Research Key players operating in the Blood-Brain Barrier market are Allon Therapeutics, Inc., Angiochem Inc., Armagen Technologies, Inc., Bristol-Myers Squibb, BiOasis Technologies, Inc., Sanofi Genzyme, CarThera, Cephalon Inc., Nanomerics, and F. Hoffman La-Roche AG. April 22, 2021 15:16 ET Surrey, CANADA Vancouver, British Columbia, April 22, 2021 (GLOBE NEWSWIRE) -- The global blood-brain barrier market size is expected to reach USD 7.40 Billion in 2028 and register a steady CAGR during the forecast period, according to latest analysis by Emergen Research. Growing awareness regarding neurological disorders, increasing healthcare expenditure, advancements in medical technology, and increasing investment in blood-brain barrier technology development are some key factors driving market revenue growth. Blood-brain barrier plays an essential role in protecting the brain from harmful compounds and blood-borne disorders. It blocks the flow of compounds from circulatory systems to the Cerebrospinal Fluid (CSF) or brain by exchanging particular components controlled by BBB or blood CSF barrier. This makes treatment for brain disorders complex due to the specialized uptake of drugs by the blood-brain barrier. Claim Your FREE Sample Copy with Table of content@ https://www.emergenresearch.com/request-sample/633 Recent advancements in drug delivery techniques enable drugs to be transferred directly to cerebrospinal fluids. There are several approaches to create a passage for delivering drugs to the brain such as passive diffusion and bispecific antibody RMT approach, Trojan horse approach, and increasing permeability. In Trojan horse approach, the drug is merged to a molecule that is able to cross the blood-brain barrier through a transporter protein. Some Key Findings From the Report: Key players operating in the market are Allon Therapeutics, Inc., Angiochem Inc., Armagen Technologies, Inc., Bristol-Myers Squibb, BiOasis Technologies, Inc., Sanofi Genzyme, CarThera, Cephalon Inc., Nanomerics, and F. Hoffman La-Roche AG. In Feb 2021, Denali Therapeutics completed a phase 1 trial of a broad portfolio of product candidates that are engineered to cross the blood-brain barrier for neurodegenerative diseases. Increasing permeability segment is expected to register a faster revenue CAGR as compared to other technology segments throughout the forecast period. This can be attributed to rising focus on research activities for treatment of many neurological and central nervous system disorders. North America accounted for a 32.3% revenue share in the global market in 2020. Major prevalence of Hunter’s Syndrome and Alzheimer's Disease, and growing adoption of advanced techniques for treating acute neurological disorders are major factors driving revenue growth of the market in this region. Check Our Prices@ https://www.emergenresearch.com/select-license/633 For the purpose of this report, Emergen Research has segmented the global blood-brain barrier (BBB) market based on application, technology, end-use, and by region: Application Outlook (Revenue, USD Billion; 2018–2028) Alzheimer’s Disease Bispecific Antibody RMT Approach Hospitals